Kushanda Kwenguva Refu KweCD19 CAR T-Cell Therapy Mukurapa Relapsed/Refractory Acute Lymphoblastic Leukemia

Mukufambira mberi kukuru munyaya dzeropa, ongororo yakaitwa munguva pfupi yapfuura yakaratidza kushanda kwenguva refu kweCD19 chimeric antigen receptor (CAR) T-cell therapy muvarwere vane relapse/refractory acute lymphoblastic leukemia (ALL) post-allogeneic hematopoietic stem cell transplantation (allo-HSCT). Chidzidzo ichi, chinotevera varwere kwenguva yakareba, chinopa ongororo yakakwana yemhedzisiro yacho, ichipa ruzivo rwakakosha pamusoro pekugara kwenguva refu uye kuchengetedzeka kwekurapa uku kutsva.

Chidzidzo ichi chakaongorora varwere vakamborapwa neCD19 CAR T-cell therapy mushure mekudzokera kuALL mushure me allo-HSCT. Mhedzisiro yacho inoratidza kuti chikamu chikuru chevarwere chakawana zororo rakazara, uye mhinduro dzakaramba dzichionekwa mumakore apfuura. Tsvagiridzo iyi haingoratidzi chete kugona kwekurapa kweCAR T-cell therapy asiwo inoratidza danho guru mukurapa kwezvirwere zveropa, kunyanya kune avo vane nzira shoma dzekurapa.

Uyezve, chidzidzo ichi chinoongorora kuchengetedzeka kwekurapa, chichitaura nezvemigumisiro inogoneka, iyo yaienderana nezvakawanikwa kare. Izvi zvinosimbisa kuvimba kuri kukura mukurapa kweCAR T-cell senzira inoshanda uye inoshanda yekurapa ALL inodzokera shure/isingadzoreki, kunyanya mushure mekuisirwa.

Sezvo munda we Kurapa nekudzivirira muviri Zvichiramba zvichienderera mberi nekushanduka, chidzidzo ichi chinoshanda sechiedza chetariro kuvarwere nevapi vehutano, zvichivimbisa ramangwana apo varwere vakawanda vanogona kuwana kuregererwa kwenguva refu. Zvakawanikwa hazvingobatsiri chete mukuwedzera kwehumbowo hunotsigira kurapwa kweCAR T-cell asiwo zvinovhura nzira yekutsvagisa kwakawedzerwa kuti zviwedzere kushandiswa kwayo munzvimbo dzekiriniki.

Nekubudirira uku, vezvekurapa vari pedyo nekushandura mamiriro ekurapa kwezvirwere zveropa, zvichipa tariro itsva kuvarwere vari kurwisana nematambudziko aya akaoma.